Net Guides: Non-Small Cell Lung Cancer

OncLive
Published: Thursday, Mar 10, 2011
//THE ONLINE ONCOLOGIST

Customization of NSCLC treatment This 97-page slideshow on the treatment of non-small cell lung cancer (NSCLC) was writtenby Professor Zarogoulidis P. Konstantinos of the Lung Tumour Research Section, Aristotle University Pulmonary Clinic, G. Papanikolaou Hospital, Thessaloniki, Greece. The presentation begins with NSCLC statistics, then moves on to define the stages of the disease with the help of colored diagrams. The slideshow goes into detailed descriptions of recommended treatments for each stage and discusses strategies such as chemotherapy, radiotherapy, adjuvant therapy, surgery, and various combination methods. Additional tables and graphs are included in the slideshow and display information such as significant milestones in lung cancer therapy and results from relevant clinical trials. The last informational section of the presentation discusses the management of NSCLC based on prognostic and predictive factors. A short series of questions and answers is provided for physicians to quiz themselves, along with Konstantinos’ conclusions and additional data from NSCLC studies.

http://tinyurl.com/2bfr4pv

//THE EDUCATED PATIENT®

NCCN guidelines for pa- tients – NSCLC This new 2010 version of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology is written specifically for patients so that they can be better informed about available treatment options for NSCLC. After the introduction, the guidelines explain issues for patients to consider and discuss with their oncologist regarding treatment. It then gives a brief overview of lung cancer staging and T, N, and M categories of lung cancer before breaking down each stage using easy-to-understand information in table format. These tables summarize the pretreatment evaluation for each stage, standard treatments used based on the evaluation, and the typical adjuvant treatments used depending on the results of initial treatment. The next sections explain follow-up, recurrence, widespread disease, therapy for recurrence, and principles of pathologic evaluation and treatment. The latter half of the document is the “Discussion version,” which provides more detailed information than the bulleted summaries in the tables and covers a wide range of topics, including diagnostic tests, types of treatment, and clinical trials. A useful glossary of terms appears at the end.

http://tinyurl.com/275qkov

//ONLINE CME

Integrating tumor histology and genetic analysis into the selection of treatment regimens in NSCLC

Credits: 0.75 Fee: None Expires: October 29, 2011

This CME activity is designed to further physicians’ understanding of the use of tumor biomarkers and histology in the treatment of NSCLC. The activity consists of a video/slideshow presented by 3 experts, and may be viewed normally or downloaded in the form of an MP3, a set of slides, or a transcript. On completing this activity, participants should be able to select appropriate treatment strategies based on tumor histology and other patient characteristics. Participants will be able to test for patients’ molecular and genetic tumor profiles, understand the results, and integrate that information into an individualized treatment plan for NSCLC for their patients.

http://tinyurl.com/26xaxbm

//eABSTRACT

Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant NSCLC: a phase II study

Journal: Journal of Thoracic Oncology Authors: Takiguchi Y, Seto T, Ichinose Y, et al Purpose: S-1 is a recently devel- oped agent that has potential activ- ity against NSCLC. The purpose of this study was to test the efficacy of S-1 in combination with gem- citabine in the second-line treat- ment of platinum-resistant NSCLC. Patients with confirmed NSCLC recurrence after prior treatment with platinum-based chemotherapy were treated with S-1 on days 1 to 14 and gemcitabine on days 8 and 15, repeated every 3 weeks until disease progression.

//CLINICAL TRIAL

Study of cetuximab with radiation followed by con- solidation chemotherapy for NSCLC

Study Type: Interventional Age/Sex Requirements: 18 years (None) Sponsor: University of Pittsburgh ClinicalTrials.gov Identifier: NCT00492206


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x